Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C77H109N21O19S |
Molecular Weight | 1664.884 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 12 / 12 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC4=CNC5=CC=CC=C45)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N6CCC[C@H]6C(=O)N[C@@H](C(C)C)C(N)=O
InChI
InChIKey=WHNFPRLDDSXQCL-UAZQEYIDSA-N
InChI=1S/C77H109N21O19S/c1-42(2)64(65(79)106)97-75(116)61-20-13-30-98(61)76(117)54(18-10-11-28-78)88-62(103)38-85-66(107)57(34-46-36-84-50-17-9-8-16-49(46)50)94-67(108)51(19-12-29-83-77(80)81)89-70(111)55(32-44-14-6-5-7-15-44)92-72(113)58(35-47-37-82-41-86-47)95-68(109)52(25-26-63(104)105)90-69(110)53(27-31-118-4)91-74(115)60(40-100)96-71(112)56(33-45-21-23-48(102)24-22-45)93-73(114)59(39-99)87-43(3)101/h5-9,14-17,21-24,36-37,41-42,51-61,64,84,99-100,102H,10-13,18-20,25-35,38-40,78H2,1-4H3,(H2,79,106)(H,82,86)(H,85,107)(H,87,101)(H,88,103)(H,89,111)(H,90,110)(H,91,115)(H,92,113)(H,93,114)(H,94,108)(H,95,109)(H,96,112)(H,97,116)(H,104,105)(H4,80,81,83)/t51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,64-/m0/s1
alpha-MELANOTROPIN (also known as an alpha-melanocyte-stimulating hormone or alpha MSH) is an endogenous melanocortin 1-receptor agonist, which exclusively expressed in cells of the melanocytic lineage. alpha-MELANOTROPIN possesses anti-inflammatory properties and antagonizes proinflammatory mediators, including TNF-alpha, IL-6 and NO, and induces anti-inflammatory cytokine IL-10. alpha-MELANOTROPIN was studied in phase I clinical trial in patients with acute renal failure. In addition, this compound was assigned of orphan designation for the treatment of chronic beryllium disease.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00004496
Patients are infused with alpha-melanocyte stimulating hormone (alpha-MSH) or placebo over 5 minutes. A cohort of 5 patients is infused at each dose level of alpha-MSH until the minimum effective dose (MED) and the maximum tolerated dose (MTD) are determined.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
308910
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
||
|
FDA ORPHAN DRUG |
106497
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4214
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
SUB30314
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
5941
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
581-05-5
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
C174814
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
16132144
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
D000521
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
m7651
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | Merck Index | ||
|
OVF025LA77
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY | |||
|
9002-79-3
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
NO STRUCTURE GIVEN | |||
|
MELANOCYTE-STIMULATING_HORMONE
Created by
admin on Fri Dec 15 16:12:06 GMT 2023 , Edited by admin on Fri Dec 15 16:12:06 GMT 2023
|
PRIMARY |
ACTIVE MOIETY